4/5
08:38 am
imux
ATOS, SMR and EIGR are among pre market gainers [Seeking Alpha]
Medium
Report
ATOS, SMR and EIGR are among pre market gainers [Seeking Alpha]
4/5
08:03 am
imux
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
4/4
08:10 am
imux
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors [Yahoo! Finance]
Low
Report
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors [Yahoo! Finance]
4/4
06:34 am
imux
Immunic to Host MS R&D Day and Participate in Investor Conferences in April [Yahoo! Finance]
Low
Report
Immunic to Host MS R&D Day and Participate in Investor Conferences in April [Yahoo! Finance]
4/4
06:30 am
imux
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Low
Report
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
3/29
11:08 pm
imux
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Neutral
Report
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/21
12:33 pm
imux
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month [Yahoo! Finance]
Low
Report
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month [Yahoo! Finance]
3/21
11:46 am
imux
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy [Yahoo! Finance]
Low
Report
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy [Yahoo! Finance]
11/14/2023
06:30 am
imux
immunic, inc.
BEAT
Report
-2.0%
immunic, inc.
8/3/2023
06:30 am
imux
immunic, inc.
MISS
Report
-0.9%
immunic, inc.
5/11/2023
06:30 am
imux
immunic, inc.
MISS
Report
0.6%
immunic, inc.
3/8
04:06 pm
imux
Form 8-K IMMUNIC, INC. For: Mar 04
Medium
Report
Form 8-K IMMUNIC, INC. For: Mar 04
3/6
09:53 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: HOWSON TAMAR D
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: HOWSON TAMAR D
3/6
09:52 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Nash Duane
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Nash Duane
3/6
09:52 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Vitt Daniel
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Vitt Daniel
3/6
09:52 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: PHILLIPS BARCLAY A
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: PHILLIPS BARCLAY A
3/6
09:51 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Toernsen Monika Maria
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Toernsen Monika Maria
3/6
09:51 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Muehler Andreas
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Muehler Andreas
3/6
09:51 pm
imux
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Whaley Glenn
Low
Report
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Whaley Glenn
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
6/24
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
90.9%
4/21
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
26.9%
3/25
Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
26.7%
3/16
Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
24.4%
12/11
Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
22.8%
7/17
Form 8-K IMMUNIC, INC. For: Jul 15
12.0%
7/30
Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
10.7%
6/4
Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway
10.2%
4/20
Form 8-K IMMUNIC, INC. For: Apr 17
9.5%
2/1
Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register